If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and allogeneic lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
